These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Risk management frameworks for human health and environmental risks. Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953 [TBL] [Abstract][Full Text] [Related]
23. Performance-based exposure control limits for pharmaceutical active ingredients. Naumann BD; Sargent EV; Starkman BS; Fraser WJ; Becker GT; Kirk GD Am Ind Hyg Assoc J; 1996 Jan; 57(1):33-42. PubMed ID: 8588551 [TBL] [Abstract][Full Text] [Related]
24. Mutagenicity assessment strategy for pharmaceutical intermediates to aid limit setting for occupational exposure. Araya S; Lovsin-Barle E; Glowienke S Regul Toxicol Pharmacol; 2015 Nov; 73(2):515-20. PubMed ID: 26454093 [TBL] [Abstract][Full Text] [Related]
25. Approaches for setting occupational exposure limits in the pharmaceutical industry. Ahuja V; Krishnappa M J Appl Toxicol; 2022 Jan; 42(1):154-167. PubMed ID: 34254327 [TBL] [Abstract][Full Text] [Related]
26. Controlling occupational exposure to hazardous drugs. Occupational Safety and Health Administration. Am J Health Syst Pharm; 1996 Jul; 53(14):1669-85. PubMed ID: 8827233 [TBL] [Abstract][Full Text] [Related]
27. An interdisciplinary framework for derivation of occupational exposure limits. Maurer LL; Alexander MS; Bachman AN; Grimm FA; Lewis RJ; North CM; Wojcik NC; Goyak KO Front Public Health; 2022; 10():1038305. PubMed ID: 36530659 [TBL] [Abstract][Full Text] [Related]
28. A review of the evidence for occupational exposure risks to novel anticancer agents - A focus on monoclonal antibodies. King J; Alexander M; Byrne J; MacMillan K; Mollo A; Kirsa S; Green M J Oncol Pharm Pract; 2016 Feb; 22(1):121-34. PubMed ID: 25227230 [TBL] [Abstract][Full Text] [Related]
29. [Biomaterial regulation (biostoffverordnung) - aspects of the practical conversion]. Kralj N Z Gastroenterol; 2002 Apr; 40 Suppl 1():S116-S8. PubMed ID: 11930306 [TBL] [Abstract][Full Text] [Related]
31. Risks to health care workers from nano-enabled medical products. Murashov V; Howard J J Occup Environ Hyg; 2015; 12(6):D75-85. PubMed ID: 25950806 [TBL] [Abstract][Full Text] [Related]
32. Identifying nonhazardous substances in pharmaceutical manufacturing and setting default health-based exposure limits (HBELs). Wiesner L; Araya S; Lovsin Barle E J Appl Toxicol; 2022 Sep; 42(9):1443-1457. PubMed ID: 35315528 [TBL] [Abstract][Full Text] [Related]
33. Establishing guidance for the handling and containment of new chemical entities and chemical intermediates in the pharmaceutical industry. Olson MJ; Binks SP; Newton DL; Clark GC Occup Med; 1997; 12(1):49-65. PubMed ID: 9153052 [TBL] [Abstract][Full Text] [Related]
34. A Framework for Hazard Banding. Laws J Occup Health Saf; 2017 May; 86(5):22-3. PubMed ID: 30285334 [TBL] [Abstract][Full Text] [Related]
35. Metalworking fluid mist occupational exposure limits: a discussion of alternative methods. Cohen H; White EM J Occup Environ Hyg; 2006 Sep; 3(9):501-7. PubMed ID: 16857649 [TBL] [Abstract][Full Text] [Related]
36. Assessing the risk to health care staff from long-term exposure to anticancer drugs--the case of monoclonal antibodies. Halsen G; Krämer I J Oncol Pharm Pract; 2011 Mar; 17(1):68-80. PubMed ID: 20667850 [TBL] [Abstract][Full Text] [Related]
37. History and evolution of control banding: a review. Zalk DM; Nelson DI J Occup Environ Hyg; 2008 May; 5(5):330-46. PubMed ID: 18350442 [TBL] [Abstract][Full Text] [Related]
38. Employee safety as a goal creates communication, cooperation, and using the best data available. Nieusma J Toxicol Mech Methods; 2011 Feb; 21(2):75. PubMed ID: 21288073 [No Abstract] [Full Text] [Related]
39. NIOSH field studies team assessment: Worker exposure to aerosolized metal oxide nanoparticles in a semiconductor fabrication facility. Brenner SA; Neu-Baker NM; Eastlake AC; Beaucham CC; Geraci CL J Occup Environ Hyg; 2016 Nov; 13(11):871-80. PubMed ID: 27171535 [TBL] [Abstract][Full Text] [Related]
40. Viral-mediated gene therapy and genetically modified therapeutics: A primer on biosafety handling for the health-system pharmacist. Blind JE; McLeod EN; Campbell KJ Am J Health Syst Pharm; 2019 May; 76(11):795-802. PubMed ID: 31361814 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]